Metformin: a promising candidate for chemoprevention of colorectal tumor and its future

Type 2 diabetes mellitus (DM) has been associated with increased risk of colorectal cancer (CRC). DM and CRC are significant health problems worldwide and have common risk factors, including obesity. In addition, they are sharing possible pathophysiological mechanisms such as hyperglycemia, hyperinsulinemia, insulin resistance, and chronic inflammation (1).